1
|
Wang D, Jiang W, Churiwal M, Jia K, Senadeera SPD, Bokesch HR, Woldemichael GM, Kim Y, Hawley RG, Wei JS, Khan J, O'Keefe BR, Beutler JA, Gustafson KR. Neopetrotaurines A-C, Isoquinoline Alkaloids with an Unprecedented Taurine Bridge from the Sponge Neopetrosia sp. J Nat Prod 2024; 87:332-339. [PMID: 38294825 DOI: 10.1021/acs.jnatprod.3c01041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
Neopetrotaurines A-C (1-3), unusual alkaloids possessing two isoquinoline-derived moieties that are linked via a unique taurine bridge, were isolated from a Neopetrosia sp. marine sponge. These new compounds have proton-deficient structural scaffolds that are difficult to unambiguously assign using only conventional 2- and 3-bond 1H-13C and 1H-15N heteronuclear correlation data. Thus, the application of LR-HSQMBC and HMBC NMR experiments optimized to detect 4- and 5-bond long-range 1H-13C heteronuclear correlations facilitated the structure elucidation of these unusual taurine-bridged marine metabolites. Neopetrotaurines A-C (1-3) showed significant inhibition of transcription driven by the oncogenic fusion protein PAX3-FOXO1, which is associated with alveolar rhabdomyosarcoma, and cytotoxic activity against PAX3-FOXO1-positive cell lines.
Collapse
Affiliation(s)
- Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Wei Jiang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
| | - Mehal Churiwal
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Katrina Jia
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Sarath P D Senadeera
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Incorporated, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Girma M Woldemichael
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
- Basic Science Program, Leidos Biomedical Research, Incorporated, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Yong Kim
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Robert G Hawley
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Jun S Wei
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Javed Khan
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - John A Beutler
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
2
|
Takada K, Oku N, Peach ML, Ransom TT, Henrich CJ, Gustafson KR. Enigmazole Phosphomacrolides from the Marine Sponge Cinachyrella enigmatica. J Org Chem 2023; 88:10996-11002. [PMID: 37471139 DOI: 10.1021/acs.joc.3c00963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/21/2023]
Abstract
Enigmazole B (1) and four new analogues, cis-enigmazole B (2), dehydroenigmazole B (3), enigmimide B (4), and enigmimide A (5), were isolated from the marine sponge Cinachyrella enigmatica. Their planar structures were elucidated by detailed NMR and MS data analyses, which established 1-3 to be oxazole-substituted 18-membered phosphomacrolides, while 4 and 5 were oxazole ring-opened congeners. The relative and absolute configurations in 1 were determined by a combination of chemical transformations and spectroscopic analyses. Photooxidation of the oxazole moiety in 1 gave enigmimide B (4), thus establishing that 4 has the same absolute configuration of 1. Enigmazole B (1) along with analogues 2 and 3 showed cytotoxicity against murine IC-2 mast cells with IC50 values of 3.6-7.0 μM. The enigmimides (4 and 5) and dephosphoenigmazoles did not show cytotoxicity (IC50 > 10 μM), implying that both the oxazole moiety and the phosphate group are necessary for the cytotoxicity of the enigmazole class macrolides.
Collapse
Affiliation(s)
- Kentaro Takada
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Naoya Oku
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Megan L Peach
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Tanya T Ransom
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Curtis J Henrich
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
3
|
Tian X, Wang D, Jiang W, Bokesch HR, Wilson BAP, O'Keefe BR, Gustafson KR. Rare Caulamidine Hexacyclic Alkaloids from the Marine Ascidian Polyandrocarpa sp. J Nat Prod 2023; 86:1855-1861. [PMID: 37368408 PMCID: PMC10732314 DOI: 10.1021/acs.jnatprod.3c00393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/28/2023]
Abstract
Two new caulamidines C (2) and D (4) and three isocaulamidines B, C, and D (1, 3, and 5) along with the known compound caulamidine B (6) were isolated from the marine ascidian Polyandrocarpa sp. Their structures were elucidated by analysis of nuclear magnetic resonance (NMR) and electronic circular dichroism (ECD) data. Isocaulamidines have an altered pattern of N-methyl substitution (N-15 vs N-13 in the caulamidines) with a concomitant double-bond rearrangement to provide a new C-14/N-13 imine functionality. Caulamidine C (2) and isocaulamidine C (3) are the first members of this alkaloid family with two chlorine substituents in the core 6H-2,6-naphthyridine ring system.
Collapse
Affiliation(s)
- Xiangrong Tian
- College of Forestry, Northwest A&F University, Yangling, Shaanxi 712100, People's Republic of China
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Wei Jiang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Brice A P Wilson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Natural Products Branch, Development Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
4
|
Sun B, Wang D, Ren J, Wang C, Yan P, Gustafson KR, Jiang W. Paraconulones A-G: Eremophilane Sesquiterpenoids from the Marine-Derived Fungus Paraconiothyrium sporulosum DL-16. J Nat Prod 2023; 86:1360-1369. [PMID: 37159940 DOI: 10.1021/acs.jnatprod.3c00221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Seven new eremophilane sesquiterpenoids, paraconulones A-G (1-7), along with three previously reported analogues, periconianone D (8), microsphaeropsisin (9), and 4-epi-microsphaeropsisin (10), were obtained from an EtOAc extract of the marine-derived fungus Paraconiothyrium sporulosum DL-16. The structures of these compounds were elucidated by extensive spectroscopic and spectrometric analyses, single-crystal X-ray diffraction, and computational studies. Compounds 1, 2, and 4 are the first examples of dimeric eremophilane sesquiterpenoids coupled through a C-C bond identified from microorganisms. Compounds 2-5, 7, and 10 showed inhibitory effects on lipopolysaccharide-induced NO production in BV2 cells, which were comparable to the positive control curcumin.
Collapse
Affiliation(s)
- Biyun Sun
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Jinwei Ren
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, People's Republic of China
| | - Chaojie Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People's Republic of China
| | - Pengcheng Yan
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People's Republic of China
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Wei Jiang
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
| |
Collapse
|
5
|
Di X, Hardardottir I, Freysdottir J, Wang D, Gustafson KR, Omarsdottir S, Molinski TF. Geobarrettin D, a Rare Herbipoline-Containing 6-Bromoindole Alkaloid from Geodia barretti. Molecules 2023; 28:molecules28072937. [PMID: 37049700 PMCID: PMC10095911 DOI: 10.3390/molecules28072937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 02/25/2023] [Accepted: 02/26/2023] [Indexed: 03/29/2023] Open
Abstract
Geobarrettin D (1), a new bromoindole alkaloid, was isolated from the marine sponge Geodia barretti collected from Icelandic waters. Its structure was elucidated by 1D, and 2D NMR (including 1H-15N HSQC, 1H-15N HMBC spectra), as well as HRESIMS data. Geobarrettin D (1) is a new 6-bromoindole featuring an unusual purinium herbipoline moiety. Geobarrettin D (1) decreased secretion of the pro-inflammatory cytokine IL-12p40 by human monocyte derived dendritic cells, without affecting secretion of the anti-inflammatory cytokine IL-10. Thus, compound 1 shows anti-inflammatory activity.
Collapse
|
6
|
Jiang W, Tian X, Wang D, Bokesch HR, Thomas CL, Woldemichael GM, Gryder BE, Wei JS, Song YK, Chou HC, Khan J, O'Keefe BR, Gustafson KR. Dentithecamides A-H, Diacylated Zoanthoxanthin Derivatives with PAX3-FOXO1 Inhibitory Activity from the Hydroid Dentitheca habereri. J Nat Prod 2022; 85:1419-1427. [PMID: 35465663 DOI: 10.1021/acs.jnatprod.2c00246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Chemical investigation of the marine hydroid Dentitheca habereri led to the identification of eight new diacylated zoanthoxanthin alkaloids, named dentithecamides A-H (1-8), along with three previously reported analogues, zoamides B-D (9-11). The structures of compounds 1-11 were elucidated by spectroscopic and spectrometric analyses, including IR, HRESIMS, and NMR experiments, and by comparison with literature data. Compounds 1-11 are the first zoanthoxanthin alkaloids to be reported from a hydroid. Dentithecamides A (1) and B (2) along with zoamides B-D (9-11), which all share a conformationally mobile cycloheptadiene core, inhibited PAX3-FOXO1 regulated transcriptional activity and thus provided a structural framework for the potential development of more potent PAX3-FOXO1 inhibitors.
Collapse
Affiliation(s)
- Wei Jiang
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Xiangrong Tian
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- College of Forestry, Northwest A&F University, Yangling 712100, People's Republic of China
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Cheryl L Thomas
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Girma M Woldemichael
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Berkley E Gryder
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio 44106, United States
| | - Jun S Wei
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Young K Song
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Hsien-Chao Chou
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Javed Khan
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
7
|
Sun PT, Cao YG, Xue GM, Li M, Zhang CL, Zhao F, Cao ZY, Wang D, Gustafson KR, Zheng XK, Feng WS, Chen H. Hypeisoxazole A, a Racemic Pair of Tetrahydroisoxazole-Fused Benzylisoquinoline Alkaloids from Hypecoum erectum and Structural Revision of Hypecoleptopine. Org Lett 2022; 24:1476-1480. [PMID: 35147434 PMCID: PMC10430687 DOI: 10.1021/acs.orglett.2c00096] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
(±)-Hypeisoxazole A (1), a racemic pair of rearranged benzylisoquinoline alkaloids possessing an unprecedented diindeno[2,1-c:2',1'-d] isoxazole scaffold, was isolated from the medicinal herb Hypecoum erectum, along with hypecoleptopine (2), whose structure is now revised as a novel spiro-benzylisoquinoline alkaloid with a 6/6/5/6/6 skeleton. Their structures were determined by comprehensive spectroscopic and spectrometric analyses, X-ray diffraction, and computational studies. Racemic mixture of 2 and its pure enantiomers modulated neuronal excitability activity.
Collapse
Affiliation(s)
- Pan-Ting Sun
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
| | - Yan-Gang Cao
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
| | - Gui-Min Xue
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
| | - Meng Li
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
| | - Chun-Lei Zhang
- State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, P. R. China
| | - Fang Zhao
- State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, P. R. China
| | - Zheng-Yu Cao
- State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, P. R. China
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Xiao-Ke Zheng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
- Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of P. R. China, Zhengzhou 450046, P. R. China
| | - Wei-Sheng Feng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
- Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of P. R. China, Zhengzhou 450046, P. R. China
| | - Hui Chen
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P. R. China
- Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan & Education Ministry of P. R. China, Zhengzhou 450046, P. R. China
| |
Collapse
|
8
|
Smith EA, Hill NT, Gelb T, Garman KA, Goncharova EI, Bokesch HR, Kim CK, Wendt KL, Cichewicz RH, Gustafson KR, Brownell I, Henrich CJ. Identification of natural product modulators of Merkel cell carcinoma cell growth and survival. Sci Rep 2021; 11:13597. [PMID: 34193920 PMCID: PMC8245553 DOI: 10.1038/s41598-021-93097-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 06/21/2021] [Indexed: 12/04/2022] Open
Abstract
Merkel cell carcinoma (MCC) is a rare, but aggressive skin cancer the incidence of which has increased significantly in recent years. The majority of MCCs have incorporated Merkel cell polyomavirus (VP-MCC) while the remainder are virus-negative (VN-MCC). Although a variety of therapeutic options have shown promise in treating MCC, there remains a need for additional therapeutics as well as probes for better understanding MCC. A high-throughput screening campaign was used to assess the ability of > 25,000 synthetic and natural product compounds as well as > 20,000 natural product extracts to affect growth and survival of VN-MCC and VP-MCC cell lines. Sixteen active compounds were identified that have mechanisms of action reported in the literature along with a number of compounds with unknown mechanisms. Screening results with pure compounds suggest a range of potential targets for MCC including DNA damage, inhibition of DNA or protein synthesis, reactive oxygen species, and proteasome inhibition as well as NFκB inhibition while also suggesting the importance of zinc and/or copper binding. Many of the active compounds, particularly some of the natural products, have multiple reported targets suggesting that this strategy might be a particularly fruitful approach. Processing of several active natural product extracts resulted in the identification of additional MCC-active compounds. Based on these results, further investigations focused on natural products sources, particularly of fungal origin, are expected to yield further potentially useful modulators of MCC.
Collapse
Affiliation(s)
- Emily A Smith
- Molecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.,Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
| | - Natasha T Hill
- Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA
| | - Tara Gelb
- Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA
| | - Khalid A Garman
- Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA
| | - Ekaterina I Goncharova
- Molecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.,Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
| | - Heidi R Bokesch
- Molecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA.,Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA
| | - Chang-Kwon Kim
- Molecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA
| | - Karen L Wendt
- Natural Products Discovery Group, Department of Chemistry & Biochemistry, Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, OK, 73019, USA
| | - Robert H Cichewicz
- Natural Products Discovery Group, Department of Chemistry & Biochemistry, Institute for Natural Products Applications and Research Technologies, University of Oklahoma, Norman, OK, 73019, USA
| | - Kirk R Gustafson
- Molecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA
| | - Isaac Brownell
- Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 20891, USA
| | - Curtis J Henrich
- Molecular Targets Program, National Cancer Institute, Frederick, MD, 21702, USA. .,Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
| |
Collapse
|
9
|
Jiang W, Wang D, Wilson BAP, Voeller D, Bokesch HR, Smith EA, Lipkowitz S, O'Keefe BR, Gustafson KR. Sinularamides A-G, Terpenoid-Derived Spermidine and Spermine Conjugates with Casitas B-Lineage Lymphoma Proto-Oncogene B (Cbl-b) Inhibitory Activities from a Sinularia sp. Soft Coral. J Nat Prod 2021; 84:1831-1837. [PMID: 34038132 PMCID: PMC9341130 DOI: 10.1021/acs.jnatprod.1c00367] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
An extract of a Sinularia sp. soft coral showed inhibitory activity against the E3-ubiquitin ligase casitas B-lineage lymphoma proto-oncogene B (Cbl-b). Subsequent bioassay-guided separation of the extract provided a series of terpenoid-derived spermidine and spermine amides that were named sinularamides A-G (1-7). Compounds 1-7 represent new natural products; however, sinularamide A (1) was previously reported as a synthetic end product. The structures of sinularamides A-G (1-7) were elucidated by analysis of spectroscopic and spectrometric data from NMR, IR, and HRESIMS experiments and by comparison with literature data. All of the isolated compounds showed Cbl-b inhibitory activities with IC50 values that ranged from approximately 6.5 to 33 μM.
Collapse
Affiliation(s)
- Wei Jiang
- Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Brice A P Wilson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Donna Voeller
- Women's Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Emily A Smith
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Stanley Lipkowitz
- Women's Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
10
|
Kim CK, Krumpe LRH, Smith E, Henrich CJ, Brownell I, Wendt KL, Cichewicz RH, O’Keefe BR, Gustafson KR. Roseabol A, a New Peptaibol from the Fungus Clonostachys rosea. Molecules 2021; 26:molecules26123594. [PMID: 34208349 PMCID: PMC8231123 DOI: 10.3390/molecules26123594] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 06/03/2021] [Accepted: 06/10/2021] [Indexed: 11/29/2022] Open
Abstract
A new 11 amino acid linear peptide named roseabol A (1) and the known compound 13-oxo-trans-9,10-epoxy-11(E)-octadecenoic acid (2) were isolated from the fungus Clonostachys rosea. Combined NMR and MS analysis revealed that roseabol A (1) contained amino acid residues characteristic of the peptaibol family of peptides such as isovaline, α-aminoisobutyric acid, hydroxyproline, leucinol, and an N-terminal isovaleric acid moiety. The amino acid sequence was established by a combination of NMR studies and tandem MS fragmentation analyses, and the absolute configurations of the constituent amino acids of 1 were determined by the advanced Marfey’s method. Compound 2 showed inhibitory activity against Merkel cell carcinoma, a rare and difficult-to-treat type of skin cancer, with an IC50 value of 16.5 μM.
Collapse
Affiliation(s)
- Chang-Kwon Kim
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; (C.-K.K.); (L.R.H.K.); (E.S.); (C.J.H.); (B.R.O.)
| | - Lauren R. H. Krumpe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; (C.-K.K.); (L.R.H.K.); (E.S.); (C.J.H.); (B.R.O.)
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - Emily Smith
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; (C.-K.K.); (L.R.H.K.); (E.S.); (C.J.H.); (B.R.O.)
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - Curtis J. Henrich
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; (C.-K.K.); (L.R.H.K.); (E.S.); (C.J.H.); (B.R.O.)
- Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - Isaac Brownell
- Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20893, USA;
| | - Karen L. Wendt
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA; (K.L.W.); (R.H.C.)
| | - Robert H. Cichewicz
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA; (K.L.W.); (R.H.C.)
| | - Barry R. O’Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; (C.-K.K.); (L.R.H.K.); (E.S.); (C.J.H.); (B.R.O.)
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21701, USA
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; (C.-K.K.); (L.R.H.K.); (E.S.); (C.J.H.); (B.R.O.)
- Correspondence: ; Tel.: +1-301-846-5197
| |
Collapse
|
11
|
Wang D, Jiang W, Kim CK, Bokesch HR, Woldemichael GM, Gryder BE, Shern JF, Khan J, O'Keefe BR, Beutler JA, Gustafson KR. Neopetrothiazide: An Intriguing Pentacyclic Thiazide Alkaloid from the Sponge Neopetrosia sp. Org Lett 2021; 23:3278-3281. [PMID: 33848174 DOI: 10.1021/acs.orglett.1c00743] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Neopetrothiazide (1), a pentacyclic isoquinoline quinone, was isolated from a Neopetrosia sp. sponge. The structure elucidation was facilitated by utilizing long-range heteronuclear single quantum multiple bond correlation (LR-HSQMBC) and heteronuclear multiple bond correlation (HMBC) nuclear magnetic resonance (NMR) pulse sequences optimized to detect four- and five-bond 1H-13C heteronuclear correlations. These NMR experiments can help assign proton-deficient structural motifs like neopetrothiazide (1), which has 14 contiguous nonprotonated centers (C, N, and S). Neopetrothiazide (1), with an unprecedented thiazide-fused structural scaffold, is the first natural product containing a thiazide moiety.
Collapse
Affiliation(s)
- Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Wei Jiang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.,Marine Science & Technology Institute, College of Environmental Science & Engineering, Yangzhou University, Yangzhou, Jiangsu 225127, People's Republic of China
| | - Chang-Kwon Kim
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.,Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Girma M Woldemichael
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.,Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Berkley E Gryder
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.,Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio 44106, United States
| | - John F Shern
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Javed Khan
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.,Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - John A Beutler
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
12
|
Tran TD, Cartner LK, Bokesch HR, Henrich CJ, Wang XW, Mahidol C, Ruchirawat S, Kittakoop P, O'Keefe BR, Gustafson KR. NMR characterization of rearranged staurosporine aglycone analogues from the marine sponge Damiria sp. Magn Reson Chem 2021; 59:534-539. [PMID: 31379005 PMCID: PMC7428849 DOI: 10.1002/mrc.4932] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 07/22/2019] [Accepted: 07/26/2019] [Indexed: 06/10/2023]
Abstract
The indolocarbazole family of bisindole alkaloids is best known for the natural product staurosporine, a protein kinase C inhibitor that belongs to the indolo[2,3-a]carbazole structural class. A large number of other indolo[2,3-a]carbazoles have subsequently been isolated and identified, but other isomeric forms of indolocarbazole natural products have rarely been reported. An extract of the marine sponge Damiria sp., which represents an understudied genus, provided two novel alkaloids named damirines A (1) and B (2). Their structures were assigned by comprehensive NMR spectroscopic analyses, and for compound 2, this included application of the LR-HSQMBC pulse sequence, a long-range heteronuclear correlation experiment that has particular utility for defining proton-deficient scaffolds. The damirines represent a new hexacyclic carbon-nitrogen framework comprised of an indolo[3,2-a]carbazole fused with either an aminoimidazole or a imidazolone ring. Compound 1 showed selective cytotoxic properties toward six different cell lines in the NCI-60 cancer screen.
Collapse
Affiliation(s)
- Trong D Tran
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD
| | - Laura K Cartner
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD
- Basic Science Program, Leidos Biomedical Research, Inc., National Cancer Institute-Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD
- Basic Science Program, Leidos Biomedical Research, Inc., National Cancer Institute-Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Curtis J Henrich
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD
- Basic Science Program, Leidos Biomedical Research, Inc., National Cancer Institute-Frederick National Laboratory for Cancer Research, Frederick, MD
| | - Xin W Wang
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Chulabhorn Mahidol
- Chulabhorn Research Institute, Office of Research, Laboratory of Natural Products, Bangkok, Thailand
- Chulabhorn Graduate Institute, Chemical Biology Program, Chulabhorn Royal Academy, Bangkok, Thailand
| | - Somsak Ruchirawat
- Chulabhorn Research Institute, Office of Research, Laboratory of Natural Products, Bangkok, Thailand
- Chulabhorn Graduate Institute, Chemical Biology Program, Chulabhorn Royal Academy, Bangkok, Thailand
- Center of Excellence on Environmental Health and Toxicology (EHT), CHE, Ministry of Education, Bangkok, Thailand
| | - Prasat Kittakoop
- Chulabhorn Research Institute, Office of Research, Laboratory of Natural Products, Bangkok, Thailand
- Chulabhorn Graduate Institute, Chemical Biology Program, Chulabhorn Royal Academy, Bangkok, Thailand
- Center of Excellence on Environmental Health and Toxicology (EHT), CHE, Ministry of Education, Bangkok, Thailand
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD
| |
Collapse
|
13
|
Abstract
Four new pregnane steroids, 3β,4β,16β-trihydroxypregna-5,17-diene-10,2-carbolactone (1), 16β-acetoxy-3β,4β-dihydroxypregna-5,17-diene-10,2-carbolactone (2), 12β-acetoxy-3β,4β,16β-trihydroxypregna-5,17-diene-10,2-carbolactone (3), and 12β,16β-diacetoxy-3β,4β-dihydroxypregna-5,17-diene-10,2-carbolactone (4) were isolated from an extract of an Epipolasis sp. marine sponge. The structures of the new compounds were determined by extensive NMR spectroscopic analysis and comparison with data from previously reported compounds.
Collapse
Affiliation(s)
- Unwoo Kang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute.,Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute
| |
Collapse
|
14
|
Abstract
Covering: July 2012 to December 2019Over the last seven years, expanding research efforts focused on sesterterpenoids has led to the isolation, identification, and characterization of numerous structurally novel and biologically active sesterterpenoids. These newly reported sesterterpenoids provide diverse structures that often incorporate unprecedented ring systems and new carbon skeletons, as well as unusual functional group arrays. Biological activities of potential biomedical importance including suppression of cancer cell growth, inhibition of enzymatic activity, and modulation of receptor signaling, as well as ecologically important functions such as antimicrobial effects and deterrence of herbivorous insects have been associated with a variety of sesterterpenoids. There has also been a rapid growth in our knowledge of the genomics, enzymology, and specific pathways associated with sesterterpene biosynthesis. This has opened up new opportunities for future sesterterpene discovery and diversification through the expression of new cryptic metabolites and the engineered manipulation of associated biosynthetic machinery and processes. In this paper we reviewed 498 new sesterterpenoids, including their structures, source organisms, country of origin, relevant bioactivities, and biosynthesis.
Collapse
Affiliation(s)
- Keke Li
- College of Life Science, Dalian Minzu University, Dalian 116600, China.
| | | |
Collapse
|
15
|
Krumpe LRH, Wilson BAP, Marchand C, Sunassee SN, Bermingham A, Wang W, Price E, Guszczynski T, Kelley JA, Gustafson KR, Pommier Y, Rosengren KJ, Schroeder CI, O'Keefe BR. Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I. J Am Chem Soc 2020; 142:21178-21188. [PMID: 33263997 DOI: 10.1021/jacs.0c10418] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a molecular target for the sensitization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irinotecan. High-throughput screening of natural product extract and fraction libraries for inhibitors of TDP1 activity resulted in the discovery of a new class of knotted cyclic peptides from the marine sponge Axinella sp. Bioassay-guided fractionation of the source extract resulted in the isolation of the active component which was determined to be an unprecedented 42-residue cysteine-rich peptide named recifin A. The native NMR structure revealed a novel fold comprising a four strand antiparallel β-sheet and two helical turns stabilized by a complex disulfide bond network that creates an embedded ring around one of the strands. The resulting structure, which we have termed the Tyr-lock peptide family, is stabilized by a tyrosine residue locked into three-dimensional space. Recifin A inhibited the cleavage of phosphodiester bonds by TDP1 in a FRET assay with an IC50 of 190 nM. Enzyme kinetics studies revealed that recifin A can specifically modulate the enzymatic activity of full-length TDP1 while not affecting the activity of a truncated catalytic domain of TDP1 lacking the N-terminal regulatory domain (Δ1-147), suggesting an allosteric binding site for recifin A on the regulatory domain of TDP1. Recifin A represents both the first of a unique structural class of knotted disulfide-rich peptides and defines a previously unseen mechanism of TDP1 inhibition that could be productively exploited for potential anticancer applications.
Collapse
Affiliation(s)
- Lauren R H Krumpe
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.,Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Brice A P Wilson
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Christophe Marchand
- Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, NCI, NIH, Bethesda, Maryland 20892, United States
| | - Suthananda N Sunassee
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Alun Bermingham
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Wenjie Wang
- Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, NCI, NIH, Bethesda, Maryland 20892, United States
| | - Edmund Price
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Tad Guszczynski
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - James A Kelley
- Chemical Biology Laboratory, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States
| | - Yves Pommier
- Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, NCI, NIH, Bethesda, Maryland 20892, United States
| | - K Johan Rosengren
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Christina I Schroeder
- Chemical Biology Laboratory, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States.,Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, NCI-Frederick, NIH, Frederick, Maryland 21702, United States.,Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702, United States
| |
Collapse
|
16
|
Kang U, Cartner LK, Wang D, Kim CK, Thomas CL, Woldemichael GM, Gryder BE, Shern JF, Khan J, Castello-Branco C, Sherer EC, Wang X, Regalado EL, Gustafson KR. Denigrins and Dactylpyrroles, Arylpyrrole Alkaloids from a Dactylia sp. Marine Sponge. J Nat Prod 2020; 83:3464-3470. [PMID: 33151696 PMCID: PMC8942300 DOI: 10.1021/acs.jnatprod.0c01103] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Seven new arylpyrrole alkaloids (1-7), along with four known compounds, were isolated from an extract of a Dactylia sp. nov. marine sponge, and their structures were elucidated by interpretation of NMR and MS spectroscopic data. Denigrins D-G (1-4) have highly substituted pyrrole or pyrrolone rings in their core structures, while dactylpyrroles A-C (5-7) have tricyclic phenanthrene cores. Due to the proton-deficient nature of these scaffolds, key heteronuclear correlations from 1H-15N HMBC and LR-HSQMBC NMR experiments were used in the structure assignment of denigrin D (1). Dictyodendrin F (8), a previously described co-metabolite, inhibited transcription driven by the oncogenic PAX3-FOXO1 fusion gene with an IC50 value of 13 μM.
Collapse
Affiliation(s)
- Unwoo Kang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Laura K Cartner
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Chang-Kwon Kim
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Cheryl L Thomas
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Girma M Woldemichael
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Berkley E Gryder
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - John F Shern
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Javed Khan
- Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Cristiana Castello-Branco
- Department of Invertebrate Zoology, National Museum of Natural History, Smithsonian Institution, Washington, D.C. 20560, United States
| | - Edward C Sherer
- Department of Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Xiao Wang
- Department of Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Erik L Regalado
- Department of Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
17
|
Kim CK, Wang D, Wilson BAP, Saurí J, Voeller D, Lipkowitz S, O’Keefe BR, Gustafson KR. Suberitamides A-C, Aryl Alkaloids from a Pseudosuberites sp. Marine Sponge that Inhibit Cbl-b Ubiquitin Ligase Activity. Mar Drugs 2020; 18:E536. [PMID: 33126420 PMCID: PMC7693676 DOI: 10.3390/md18110536] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 10/15/2020] [Accepted: 10/22/2020] [Indexed: 12/20/2022] Open
Abstract
Three new aryl alkaloids named suberitamides A-C (1-3), were isolated from an extract of the marine sponge Pseudosuberites sp. collected along the coast of North Carolina. Their planar structures were established by extensive nuclear magnetic resonance (NMR) and mass spectrometry (MS) analysis. To assign the challenging relative configuration of the saturated five-membered ring in suberitamide A (1), a simple and efficient NMR protocol was applied that is based on the analysis of 2- and 3-bond 1H-13C spin-spin coupling constants using a PIP (pure in-phase) HSQMBC (heteronuclear single quantum multiple bond correlation) IPAP (in-phase and anti-phase) experiment. Suberitamides A (1) and B (2) inhibited Cbl-b, an E3 ubiquitin ligase that is an important modulator of immune cell function, with IC50 values of approximately 11 μM.
Collapse
Affiliation(s)
- Chang-Kwon Kim
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA; (C.-K.K.); (D.W.); (B.A.P.W.); (B.R.O.)
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA; (C.-K.K.); (D.W.); (B.A.P.W.); (B.R.O.)
| | - Brice A. P. Wilson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA; (C.-K.K.); (D.W.); (B.A.P.W.); (B.R.O.)
| | - Josep Saurí
- Structure Elucidation Group, Analytical Research and Development, Merck & Co., Inc., Boston, MS 02115, USA;
| | - Donna Voeller
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1578, USA; (D.V.); (S.L.)
| | - Stanley Lipkowitz
- Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1578, USA; (D.V.); (S.L.)
| | - Barry R. O’Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA; (C.-K.K.); (D.W.); (B.A.P.W.); (B.R.O.)
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21701-1201, USA
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA; (C.-K.K.); (D.W.); (B.A.P.W.); (B.R.O.)
| |
Collapse
|
18
|
van der Westhuyzen AE, Ingels A, Rosière R, Amighi K, Oberer L, Gustafson KR, Wang D, Evidente A, Maddau L, Masi M, de Villiers A, Green IR, Berger W, Kornienko A, Mathieu V, van Otterlo WAL. Deciphering the chemical instability of sphaeropsidin A under physiological conditions - degradation studies and structural elucidation of the major metabolite. Org Biomol Chem 2020; 18:8147-8160. [PMID: 33016969 PMCID: PMC7881364 DOI: 10.1039/d0ob01586e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The fungal metabolite sphaeropsidin A (SphA) has been recognised for its promising cytotoxicity, particularly towards apoptosis- and multidrug-resistant cancers. Owing to its intriguing activity, the development of SphA as a potential anticancer agent has been pursued. However, this endeavour is compromised since SphA exhibits poor physicochemical stability under physiological conditions. Herein, SphA's instability in biological media was explored utilizing LC-MS. Notably, the degradation tendency was found to be markedly enhanced in the presence of amino acids in the cell medium utilized. Furthermore, the study investigated the presence of degradation adducts, including the identification, isolation and structural elucidation of a major degradation metabolite, (4R)-4,4',4'-trimethyl-3'-oxo-4-vinyl-4',5',6',7'-tetrahydro-3'H-spiro[cyclohexane-1,1'-isobenzofuran]-2-ene-2-carboxylic acid. Considering the reduced cytotoxic potency of aged SphA solutions, as well as that of the isolated degradation metabolite, the reported antiproliferative activity has been attributed primarily to the parent compound (SphA) and not its degradation species. The fact that SphA continues to exhibit remarkable bioactivity, despite being susceptible to degradation, motivates future research efforts to address the challenges associated with this instability impediment.
Collapse
Affiliation(s)
- Alet E van der Westhuyzen
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| | - Aude Ingels
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. and ULB Cancer Research Center, Université libre de Bruxelles (ULB), 1050 Bruxelles, Belgium
| | - Rémi Rosière
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium.
| | - Karim Amighi
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium.
| | - Lukas Oberer
- Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel, Switzerland
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, USA
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, USA
| | - Antonio Evidente
- Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy
| | - Lucia Maddau
- Department of Agriculture, Section of Plant Pathology and Entomology, University of Sassari, Viale Italia 39, 07100, Sassari, Italy
| | - Marco Masi
- Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte S. Angelo, Via Cintia 4, 80126 Naples, Italy
| | - André de Villiers
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| | - Ivan R Green
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| | - Walter Berger
- Department of Medicine I, Institute of Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, Texas 78666, USA
| | - Veronique Mathieu
- Department of Pharmacotherapy and Pharmaceutics, Université libre de Bruxelles (ULB), Boulevard du Triomphe, Accès 2, 1050 Ixelles, Belgium. and ULB Cancer Research Center, Université libre de Bruxelles (ULB), 1050 Bruxelles, Belgium
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, 7600, Stellenbosch, Western Cape, South Africa.
| |
Collapse
|
19
|
Tran TD, Wilson BAP, Henrich CJ, Wendt KL, King J, Cichewicz RH, Stchigel AM, Miller AN, O'Keefe BR, Gustafson KR. Structure elucidation and absolute configuration of metabolites from the soil-derived fungus Dictyosporium digitatum using spectroscopic and computational methods. Phytochemistry 2020; 173:112278. [PMID: 32078832 PMCID: PMC7124996 DOI: 10.1016/j.phytochem.2020.112278] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Revised: 01/13/2020] [Accepted: 01/14/2020] [Indexed: 06/10/2023]
Abstract
Following the discovery of a new class of compounds that inhibit the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) protease in a prior study, further chemical investigation of the Dictyosporium digitatum fungus resulted in the identification of 16 additional metabolites, including 12 undescribed compounds (1-12). The constitution and relative configuration of these new molecules were established by comprehensive NMR and HRMS analyses. Their absolute configurations were determined by employing Mosher's ester analysis and TDDFT ECD calculations. Two sesquiterpenes, dictyosporins A (1) and B (2), possess an undescribed eudesmen-type of structural scaffold. The ability of the isolated compounds to inhibit MALT1 proteolytic activity was evaluated, but none of them exhibited significant inhibition.
Collapse
Affiliation(s)
- Trong D Tran
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, United States
| | - Brice A P Wilson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, United States
| | - Curtis J Henrich
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, United States; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702-1201, United States
| | - Karen L Wendt
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, 73019-5251, United States
| | - Jarrod King
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, 73019-5251, United States
| | - Robert H Cichewicz
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, 73019-5251, United States
| | - Alberto M Stchigel
- Mycology Unit, Universitat Rovira i Virgili, C/ Sant Llorenç 21, 43201, Reus, Spain
| | - Andrew N Miller
- University of Illinois, Illinois Natural History Survey, 1816 South Oak Street, Champaign, IL, 61820-6970, United States
| | - Barry R O'Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, United States; Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD, 21702-1201, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, United States.
| |
Collapse
|
20
|
Kim CK, Wang D, Bokesch HR, Fuller RW, Smith E, Henrich CJ, Durrant DE, Morrison DK, Bewley CA, Gustafson KR. Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction. J Nat Prod 2020; 83:1288-1294. [PMID: 32191460 PMCID: PMC7183427 DOI: 10.1021/acs.jnatprod.0c00136] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea. They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus. Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies. Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue. Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
Collapse
Affiliation(s)
- Chang-Kwon Kim
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R. Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Richard W. Fuller
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Emily Smith
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Curtis J. Henrich
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - David E. Durrant
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Deborah K. Morrison
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Carole A. Bewley
- Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20814, United States
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
21
|
Grkovic T, Akee RK, Thornburg CC, Trinh SK, Britt JR, Harris MJ, Evans JR, Kang U, Ensel S, Henrich CJ, Gustafson KR, Schneider JP, O’Keefe BR. National Cancer Institute (NCI) Program for Natural Products Discovery: Rapid Isolation and Identification of Biologically Active Natural Products from the NCI Prefractionated Library. ACS Chem Biol 2020; 15:1104-1114. [PMID: 32223208 PMCID: PMC7171602 DOI: 10.1021/acschembio.0c00139] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 03/30/2020] [Indexed: 01/21/2023]
Abstract
An automated, high-capacity, and high-throughput procedure for the rapid isolation and identification of biologically active natural products from a prefractionated library is presented. The semipreparative HPLC method uses 1 mg of the primary hit fraction and produces 22 subfractions in an assay-ready format. Following screening, all active fractions are analyzed by NMR, LCMS, and FTIR, and the active principle structural classes are elucidated. In the proof-of-concept study, we show the processes involved in generating the subfractions, the throughput of the structural elucidation work, as well as the ability to rapidly isolate and identify new and biologically active natural products. Overall, the rapid second-stage purification conserves extract mass, requires much less chemist time, and introduces knowledge of structure early in the isolation workflow.
Collapse
Affiliation(s)
- Tanja Grkovic
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Rhone K. Akee
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Christopher C. Thornburg
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Spencer K. Trinh
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - John R. Britt
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Matthew J. Harris
- Natural
Products Support Group, Leidos Biomedical
Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Jason R. Evans
- Natural
Products Branch, Developmental Therapeutics Program, Division of Cancer
Treatment and Diagnosis, National Cancer
Institute, Frederick, Maryland 21702-1201, United States
| | - Unwoo Kang
- Molecular
Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Susan Ensel
- Department
of Chemistry and Physics, Hood College, Frederick, Maryland 21701-8599, United States
| | - Curtis J. Henrich
- Molecular
Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic
Science Program, Leidos Biomedical Research,
Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular
Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Joel P. Schneider
- Chemical
Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Barry R. O’Keefe
- Natural
Products Branch, Developmental Therapeutics Program, Division of Cancer
Treatment and Diagnosis, National Cancer
Institute, Frederick, Maryland 21702-1201, United States
- Molecular
Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
22
|
Strope JD, Peer CJ, Sissung TM, Hall OM, Huang PA, Harris EM, Gustafson KR, Henrich CJ, Sigano DM, Pauly GT, Schneider JP, Bates SE, Figg WD. Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer Biol Ther 2019; 21:223-230. [PMID: 31709896 PMCID: PMC7012088 DOI: 10.1080/15384047.2019.1683324] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Accepted: 10/06/2019] [Indexed: 01/10/2023] Open
Abstract
Introduction: Transporters comprising the blood-brain barrier complicate delivery of many therapeutics to the central nervous system. The present study ascertained whether the natural product botryllamide G is viable for in vivo inhibition of ABCG2 using lapatinib as a probe for ABCB1 and ABCG2-mediated efflux from the brain. Methods: Wild-type and Mdr1a/Mdr1b (-/-) mice were treated with botryllamide G and lapatinib ("doublet therapy"), and while a separate cohort of wild-type mice was treated with botryllamide, tariquidar and lapatinib ("triplet therapy"). Results: Botryllamide G demonstrates biphasic elimination with a rapid distribution, decreasing below the in vitro IC50 of 6.9 µM within minutes, yet with a relatively slower terminal half-life (4.6 h). In Mdr1a/Mdr1b (-/-) mice, doublet therapy resulted in a significant increase in brain lapatinib AUC at 8 h (2058 h*ng/mL vs 4007 h*ng/mL; P = .031), but not plasma exposure (P = .15). No significant differences were observed after 24 h. Lapatinib brain exposure was greater through 1 h when wild-type mice were administered triplet therapy (298 h*pg/mg vs 120 h*pg/mg; P < .001), but the triplet decreased brain AUC through 24 h vs. mice administered lapatinib alone (2878 h*pg/mg vs 4461hr*ng/mL; P < .001) and did not alter the brain:plasma ratio. Conclusions: In summary, the ABCG2 inhibitor, botryllamide G, increases brain exposure to lapatinib in mice lacking Abcb1, although the combination of botryllamide G and tariquidar increases brain exposure in wild-type mice only briefly (1 h). Additional research is needed to find analogs of this compound that have better pharmacokinetics and pharmacodynamic effects on ABCG2 inhibition.
Collapse
Affiliation(s)
- Jonathan D. Strope
- Molecular Pharmacology Section, National Cancer Institute, Bethesda, MD, USA
| | - Cody J. Peer
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
| | - Tristan M. Sissung
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
| | - O. Morgan Hall
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
| | - Phoebe A. Huang
- Molecular Pharmacology Section, National Cancer Institute, Bethesda, MD, USA
| | - Emily M. Harris
- Molecular Pharmacology Section, National Cancer Institute, Bethesda, MD, USA
| | - Kirk R. Gustafson
- Molecular Targets Program, National Cancer Institute, Frederick, MD, USA
| | - Curtis J. Henrich
- Molecular Targets Program, National Cancer Institute, Frederick, MD, USA
- Basic Research Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Dina M. Sigano
- Chemical Biology Laboratory, National Cancer Institute, Frederick, MD, USA
| | - Gary T. Pauly
- Chemical Biology Laboratory, National Cancer Institute, Frederick, MD, USA
| | - Joel P. Schneider
- Chemical Biology Laboratory, National Cancer Institute, Frederick, MD, USA
| | - Susan E. Bates
- Department of Medicine, Division of Hematology and Oncology, Columbia University, New York, NY, USA
| | - William D. Figg
- Molecular Pharmacology Section, National Cancer Institute, Bethesda, MD, USA
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA
| |
Collapse
|
23
|
Yan P, Li G, Wang C, Wu J, Sun Z, Martin GE, Wang X, Reibarkh M, Saurí J, Gustafson KR. Characterization by Empirical and Computational Methods of Dictyospiromide, an Intriguing Antioxidant Alkaloid from the Marine Alga Dictyota coriacea. Org Lett 2019; 21:7577-7581. [PMID: 31539931 PMCID: PMC7487124 DOI: 10.1021/acs.orglett.9b02856] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The challenging structural motif of dictyospiromide (1), a spirosuccinimide alkaloid with antioxidant properties that are associated with activation of the Nrf2/ARE signaling pathway, was assigned using contemporary NMR experiments complemented with anisotropic NMR, chiroptical, and computational methodologies. Anisotropic NMR parameters provided critical orthogonal verification of the configuration of the difficult to assign spiro carbon and the other stereogenic centers in 1.
Collapse
Affiliation(s)
- Pengcheng Yan
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
| | - Ge Li
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
| | - Chaojie Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
| | - Jianzhang Wu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
| | - Zhongmin Sun
- Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, People’s Republic of China
| | - Gary E. Martin
- Department of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States
| | - Xiao Wang
- Structure Elucidation Group, Analytical Research and Development, Merck & Co., Rahway, New Jersey 07065, United States
| | - Mikhail Reibarkh
- Structure Elucidation Group, Analytical Research and Development, Merck & Co., Rahway, New Jersey 07065, United States
| | - Josep Saurí
- Structure Elucidation Group, Analytical Research and Development, Merck & Co., Boston, Massachusetts 02115, United States
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
| |
Collapse
|
24
|
Valdeira ASC, Darvishi E, Woldemichael GM, Beutler JA, Gustafson KR, Salvador JAR. Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation. J Nat Prod 2019; 82:2094-2105. [PMID: 31343174 PMCID: PMC7428852 DOI: 10.1021/acs.jnatprod.8b00864] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A series of novel madecassic acid (1) derivatives was synthesized, and their cytotoxicity was evaluated against the NCI-60 panel of cancer cell lines. Several analogues exhibited broad-spectrum cytotoxic activities over all nine tumor types represented in the panel, with more potent antiproliferative activities observed against selected cancer cell lines, including multidrug-resistant phenotypes. Among them, compound 29 showed GI50 (50% growth inhibition) values ranging from 0.3 to 0.9 μM against 26 different tumor cell lines and selectivity for one colon (COLO 205) and two melanoma (SK-MEL-5 and UACC-257) cell lines at the TGI (total growth inhibition) level. The mode of action of 29 was predicted by CellMiner bioinformatic analysis and confirmed by biochemical and cell-based experiments to involve inhibition of the DNA replication process, particularly the initiation of replication, and disruption of mitochondrial membrane potential. The present findings suggest this novel madecassic acid derivative may have potential as an anticancer therapeutic lead for both solid and hematological tumors.
Collapse
Affiliation(s)
- Ana S. C. Valdeira
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal
- Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Emad Darvishi
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Girma M. Woldemichael
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - John A. Beutler
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States
| | - Jorge A. R. Salvador
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal
- Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal
| |
Collapse
|
25
|
Kang U, Caldwell DR, Cartner LK, Wang D, Kim CK, Tian X, Bokesch HR, Henrich CJ, Woldemichael GM, Schnermann MJ, Gustafson KR. Elucidation of Spirodactylone, a Polycyclic Alkaloid from the Sponge Dactylia sp., and Nonenzymatic Generation from the Co-metabolite Denigrin B. Org Lett 2019; 21:4750-4753. [PMID: 31150264 DOI: 10.1021/acs.orglett.9b01636] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Spirodactylone (1), a hexacyclic indolizidone alkaloid possessing a novel spiro ring system, was isolated from the marine sponge Dactylia sp. The structure was elucidated by extensive spectroscopic methods including application of the LR-HSQMBC NMR pulse sequence. Oxidative cyclization of denigrin B (2), an aryl-substituted 2-oxo-pyrroline derivative that was also isolated from the sponge extract, provided material identical to spirodactylone (1). This confirmed the assigned structure and provides insight into the probable biogenesis of 1.
Collapse
Affiliation(s)
- Unwoo Kang
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Donald R Caldwell
- Chemical Biology Laboratory, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Laura K Cartner
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States.,Basic Science Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Dongdong Wang
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Chang-Kwon Kim
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Xiangrong Tian
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States.,Research & Development Center of Biorational Pesticide, College of Plant Protection , Northwest A&F University , Yangling 712100 , P. R. China
| | - Heidi R Bokesch
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States.,Basic Science Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Curtis J Henrich
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States.,Basic Science Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Girma M Woldemichael
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States.,Basic Science Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Martin J Schnermann
- Chemical Biology Laboratory, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , United States
| |
Collapse
|
26
|
Tran TD, Wilson BAP, Henrich CJ, Staudt LM, Krumpe LRH, Smith EA, King J, Wendt KL, Stchigel AM, Miller AN, Cichewicz RH, O’Keefe BR, Gustafson KR. Secondary Metabolites from the Fungus Dictyosporium sp. and Their MALT1 Inhibitory Activities. J Nat Prod 2019; 82:154-162. [PMID: 30600998 PMCID: PMC7462088 DOI: 10.1021/acs.jnatprod.8b00871] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Bioassay-guided separation of an extract from a Dictyosporium sp. isolate led to the identification of six new compounds, 1-6, together with five known compounds, 7-11. The structures of the new compounds were primarily established by extensive 1D and 2D NMR experiments. The absolute configurations of compounds 3-6 were determined by comparison of their experimental electronic circular dichroism (ECD) spectra with DFT quantum mechanical calculated ECD spectra. Compounds 3-5 possess novel structural scaffolds, and biochemical studies revealed that oxepinochromenones 1 and 7 inhibited the activity of MALT1 protease.
Collapse
Affiliation(s)
- Trong D. Tran
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - Brice A. P. Wilson
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - Curtis J. Henrich
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Louis M. Staudt
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Lauren R. H. Krumpe
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Emily A. Smith
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Jarrod King
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Karen L. Wendt
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Alberto M. Stchigel
- Mycology Unit, Universitat Rovira i Virgili, C/Sant Llorenç 21, 43201 Reus, Spain
| | - Andrew N. Miller
- Illinois Natural History Survey, University of Illinois, 1816 South Oak Street, Champaign, Illinois 61820-6970, United States
| | - Robert H. Cichewicz
- Natural Products Discovery Group, Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019-5251, United States
| | - Barry R. O’Keefe
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - Kirk R. Gustafson
- Molecular Targets Program, Center of Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States
- Corresponding Author Tel: +1-301-846-5197. Fax: +1-301-846-6851.
| |
Collapse
|
27
|
Kim HJ, Yim SH, Han F, Kang BY, Choi HJ, Jung DW, Williams DR, Gustafson KR, Kennelly EJ, Lee IS. Biotransformed Metabolites of the Hop Prenylflavanone Isoxanthohumol. Molecules 2019; 24:molecules24030394. [PMID: 30678278 PMCID: PMC6385124 DOI: 10.3390/molecules24030394] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2018] [Revised: 01/18/2019] [Accepted: 01/20/2019] [Indexed: 02/07/2023] Open
Abstract
A metabolic conversion study on microbes is known as one of the most useful tools to predict the xenobiotic metabolism of organic compounds in mammalian systems. The microbial biotransformation of isoxanthohumol (1), a major hop prenylflavanone in beer, has resulted in the production of three diastereomeric pairs of oxygenated metabolites (2–7). The microbial metabolites of 1 were formed by epoxidation or hydroxylation of the prenyl group, and HPLC, NMR, and CD analyses revealed that all of the products were diastereomeric pairs composed of (2S)- and (2R)- isomers. The structures of these metabolic compounds were elucidated to be (2S,2″S)- and (2R,2″S)-4′-hydroxy-5-methoxy-7,8-(2,2-dimethyl-3-hydroxy-2,3-dihydro-4H-pyrano)-flavanones (2 and 3), (2S)- and (2R)-7,4′-dihydroxy-5-methoxy-8-(2,3-dihydroxy-3-methylbutyl)-flavanones (4 and 5) which were new oxygenated derivatives, along with (2R)- and (2S)-4′-hydroxy-5-methoxy-2″-(1-hydroxy-1-methylethyl)dihydrofuro[2,3-h]flavanones (6 and 7) on the basis of spectroscopic data. These results could contribute to understanding the metabolic fates of the major beer prenylflavanone isoxanthohumol that occur in mammalian system.
Collapse
Affiliation(s)
- Hyun Jung Kim
- College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan, Jeonnam 58554, Korea.
| | - Soon-Ho Yim
- Department of Pharmaceutical Engineering, Dongshin University, Naju, Jeonnam 58245, Korea.
| | - Fubo Han
- College of Pharmacy, Chonnam National University, Gwangju 61186, Korea.
| | - Bok Yun Kang
- College of Pharmacy, Chonnam National University, Gwangju 61186, Korea.
| | - Hyun Jin Choi
- College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, Seongnam, Gyeonggi-do 13488, Korea.
| | - Da-Woon Jung
- New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
| | - Darren R Williams
- New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, Korea.
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
| | - Edward J Kennelly
- Department of Biological Sciences, Lehman College, City University of New York, Bronx, NY 10468, USA.
| | - Ik-Soo Lee
- College of Pharmacy, Chonnam National University, Gwangju 61186, Korea.
| |
Collapse
|
28
|
Singh AJ, Gorka AP, Bokesch HR, Wamiru A, O’Keefe BR, Schnermann MJ, Gustafson KR. Harnessing Natural Product Diversity for Fluorophore Discovery: Naturally Occurring Fluorescent Hydroxyanthraquinones from the Marine Crinoid Pterometra venusta. J Nat Prod 2018; 81:2750-2755. [PMID: 30495954 PMCID: PMC6474788 DOI: 10.1021/acs.jnatprod.8b00761] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Fluorescent small molecules are important tools in many aspects of modern biology. A two-stage evaluation process involving fluorescence screening and live-cell imaging was developed to facilitate the identification of new fluorescent probes from extracts housed within the NCI Natural Products Repository. To this end, over 2000 extracts and prefractionated samples were examined, including an extract from the marine crinoid Pterometra venusta. An optically guided evaluation involving stepwise fluorescence screening and live-cell imaging was developed to enable the isolation of fluorescent natural products. These efforts resulted in the isolation of six hydroxyanthraquinone compounds, three of which are new natural products. These purified metabolites were examined for their potential as cellular imaging probes, and they demonstrate that natural product libraries can be a good source of new fluorescent agents.
Collapse
Affiliation(s)
- A. Jonathan Singh
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Alexander P. Gorka
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R. Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Antony Wamiru
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Barry R. O’Keefe
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21701-1201, United States
| | - Martin J. Schnermann
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Corresponding Authors:.,
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Corresponding Authors:.,
| |
Collapse
|
29
|
Valdeira ASC, Ritt DA, Morrison DK, McMahon JB, Gustafson KR, Salvador JAR. Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling. Front Chem 2018; 6:434. [PMID: 30324102 PMCID: PMC6172662 DOI: 10.3389/fchem.2018.00434] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 09/03/2018] [Indexed: 01/29/2023] Open
Abstract
In the present study, a series of novel madecassic acid derivatives was synthesized and screened against the National Cancer Institute's 60 human cancer cell line panel. Among them, compounds 5, 12, and 17 displayed potent and highly differential antiproliferative activity against 80% of the tumor cells harboring the B-RafV600E mutation within the nanomolar range. Structure-activity analysis revealed that a 5-membered A ring containing an α,β-unsaturated aldehyde substituted at C-23 with a 2-furoyl group seems to be crucial to produce this particular growth inhibition signature. In silico analysis of the cytotoxicity pattern of these compounds identified two highly correlated clinically approved drugs with known B-RafV600E inhibitory activity. Follow-up analysis revealed inhibition of the ERK signaling pathway through the reduction of cellular Raf protein levels is a key mechanism of action of these compounds. In particular, 17 was the most potent compound in suppressing tumor growth of B-RafV600E-mutant cell lines and displayed the highest reduction of Raf protein levels among the tested compounds. Taken together, this study revealed that modifications of madecassic acid structure can provide molecules with potent anticancer activity against cell lines harboring the clinically relevant B-RafV600E mutation, with compound 17 identified as a promising lead for the development of new anticancer drugs.
Collapse
Affiliation(s)
- Ana S C Valdeira
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.,Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
| | - Daniel A Ritt
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - Deborah K Morrison
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - James B McMahon
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - Kirk R Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - Jorge A R Salvador
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.,Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
30
|
Yan P, Ritt DA, Zlotkowski K, Bokesch HR, Reinhold WC, Schneekloth JS, Morrison DK, Gustafson KR. Macrophilones from the Marine Hydroid Macrorhynchia philippina Can Inhibit ERK Cascade Signaling. J Nat Prod 2018; 81:1666-1672. [PMID: 29979591 PMCID: PMC6319658 DOI: 10.1021/acs.jnatprod.8b00343] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Six new macrophilone-type pyrroloiminoquines were isolated and identified from an extract of the marine hydroid Macrorhynchia philippina. The proton-deficient and heteroatom-rich structures of macrophilones B-G (2-7) were elucidated by spectroscopic analysis and comparison of their data with those of the previously reported metabolite macrophilone A (1). Compounds 1-7 are the first pyrroloiminoquines to be reported from a hydroid. The macrophilones were shown to inhibit the enzymatic conjugation of SUMO to peptide substrates, and macrophilones A (1) and C (3) exhibit potent and selective cytotoxic properties in the NCI-60 anticancer screen. Bioinformatic analysis revealed a close association of the cytotoxicity profiles of 1 and 3 with two known B-Raf kinase inhibitory drugs. While compounds 1 and 3 showed no kinase inhibitory activity, they resulted in a dramatic decrease in cellular protein levels of selected components of the ERK signal cascade. As such, the chemical scaffold of the macrophilones could provide small-molecule therapeutic leads that target the ERK signal transduction pathway.
Collapse
Affiliation(s)
- Pengcheng Yan
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People’s Republic of China
| | - Daniel A. Ritt
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Katherine Zlotkowski
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R. Bokesch
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - William C. Reinhold
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - John S. Schneekloth
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Deborah K. Morrison
- Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
31
|
Strope JD, Harris EM, Beedie SL, Chau CH, Cook KM, Schofield CJ, Gustafson KR, Figg WD. Abstract 14: Preclinical evaluation of novel HIF-1α/P300 binding inhibitors. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A key component of tumor progression and metastasis is the hypoxic response. The hypoxic response regulates angiogenesis, tumor invasion, and metabolism. The Hypoxia Inducible Factor (HIF) is the transcriptional system responsible for the hypoxic response. The inhibition of the hypoxic response via inhibition of the HIF-1 pathway by disrupting its association with the transcriptional coactivator p300 presents a potential therapeutic target for multiple cancers where HIF is upregulated. To that end, we describe the preclinical development of previously described novel marine pyrroloiminoquinone alkaloids found using a HIF-1α/p300 assay in a high throughput screen of extracts from the National Cancer Institute's Natural Products Repository. Pyrroloiminoquinone alkaloids are a novel class of HIF-1α inhibitors, which interrupt the protein−protein interaction between HIF-1α and p300 and consequently reduce HIF-related transcription. The 2 lead candidates, discorhabdin L and H were assessed in inhibition of angiogenesis in an in vitro HUVEC assay and ex vivo rat aortic ring assay. The compounds were also evaluated for in vivo efficacy in prostate cancer cell tumor xenografts. Results show that development of these compounds for clinical use is warranted and may prevent the progression of multiple tumor types.
Citation Format: Jonathan D. Strope, Emily M. Harris, Shaunna L. Beedie, Cindy H. Chau, Kristina M. Cook, Christopher J. Schofield, Kirk R. Gustafson, William D. Figg. Preclinical evaluation of novel HIF-1α/P300 binding inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 14.
Collapse
|
32
|
Espindola LS, Dusi RG, Demarque DP, Braz-Filho R, Yan P, Bokesch HR, Gustafson KR, Beutler JA. Cytotoxic Triterpenes from Salacia crassifolia and Metabolite Profiling of Celastraceae Species. Molecules 2018; 23:molecules23061494. [PMID: 29925807 PMCID: PMC6099938 DOI: 10.3390/molecules23061494] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Revised: 06/15/2018] [Accepted: 06/18/2018] [Indexed: 01/12/2023] Open
Abstract
The new pentacyclic triterpene 11β-hydroxypristimerin (1), along with the known metabolites pristimerin (2), 6-oxopristimerol (3) and vitideasin (4), were isolated from a Salacia crassifolia root wood extract, following a bioassay-guided fractionation approach. Both the extract and the purified triterpenes displayed pronounced cytotoxic activity against human cancer cell lines. The NCI-60 cell line screen revealed that compound 2 was the most active, with a mean GI50 of 0.17 μM, while compound 1 had a mean GI50 of 8.7 μM. A COMPARE analysis of the screening results showed that pristimerin is likely to be the main compound responsible for the cytotoxic activity of the extract (mean GI50 of 0.3 μg·mL−1). A targeted search for pristimerin and related derivatives using LC-MS/MS revealed the presence of pristimerin (2) and 6-oxopristimerol (3) in all Celastraceae species examined and in all plant parts tested, while vitideasin (4) was only detected in the genus Salacia.
Collapse
Affiliation(s)
- Laila S Espindola
- Laboratório de Farmacognosia, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Brasília 70910-900, Brazil.
- Molecular Targets Program, National Cancer Institute, Frederick, MD 21702, USA.
| | - Renata G Dusi
- Laboratório de Farmacognosia, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Brasília 70910-900, Brazil.
- Molecular Targets Program, National Cancer Institute, Frederick, MD 21702, USA.
| | - Daniel P Demarque
- Laboratório de Farmacognosia, Universidade de Brasília, Campus Universitário Darcy Ribeiro, Brasília 70910-900, Brazil.
| | - Raimundo Braz-Filho
- FAPERJ/Departamento de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, RJ and Laboratório de Ciências Químicas, Universidade Estadual do Norte Fluminense, Campos dos Goytacazes, Rio de Janeiro 28013-602, Brazil.
| | - Pengcheng Yan
- Molecular Targets Program, National Cancer Institute, Frederick, MD 21702, USA.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
| | - Heidi R Bokesch
- Molecular Targets Program, National Cancer Institute, Frederick, MD 21702, USA.
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
| | - Kirk R Gustafson
- Molecular Targets Program, National Cancer Institute, Frederick, MD 21702, USA.
| | - John A Beutler
- Molecular Targets Program, National Cancer Institute, Frederick, MD 21702, USA.
| |
Collapse
|
33
|
Liu Y, Cohen RD, Gustafson KR, Martin GE, Williamson RT. Enhanced measurement of residual chemical shift anisotropy for small molecule structure elucidation. Chem Commun (Camb) 2018; 54:4254-4257. [PMID: 29505044 PMCID: PMC6322199 DOI: 10.1039/c8cc00552d] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
A method is introduced to measure residual chemical shift anisotropies conveniently and accurately in the mesophase of poly-γ-(benzyl-l-glutamate). The alignment amplitude is substantially enhanced over common methods which greatly benefits measurements particularly on sp3 carbons. The approach offers significant improvements in data accuracy and utility for small molecule structure determination.
Collapse
Affiliation(s)
- Yizhou Liu
- Structure Elucidation Group, Process and Analytical Research and Development, Merck & Co. Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA.
| | | | | | | | | |
Collapse
|
34
|
Milanowski DJ, Oku N, Cartner LK, Bokesch HR, Williamson RT, Saurí J, Liu Y, Blinov KA, Ding Y, Li XC, Ferreira D, Walker LA, Khan S, Davies-Coleman MT, Kelley JA, McMahon JB, Martin GE, Gustafson KR. Unequivocal determination of caulamidines A and B: application and validation of new tools in the structure elucidation tool box. Chem Sci 2017; 9:307-314. [PMID: 29619201 PMCID: PMC5868047 DOI: 10.1039/c7sc01996c] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 11/03/2017] [Indexed: 01/21/2023] Open
Abstract
Newly described NMR experimental approaches can provide valuable structural details and a complementary means of structure verification.
Ambiguities and errors in the structural assignment of organic molecules hinder both drug discovery and total synthesis efforts. Newly described NMR experimental approaches can provide valuable structural details and a complementary means of structure verification. The caulamidines are trihalogenated alkaloids from a marine bryozoan with an unprecedented structural scaffold. Their unique carbon and nitrogen framework was deduced by conventional NMR methods supplemented by new experiments that define 2-bond heteronuclear connectivities, reveal very long-range connectivity data, or visualize the 35,37Cl isotopic effect on chlorinated carbons. Computer-assisted structural elucidation (CASE) analysis of the spectroscopic data for caulamidine A provided only one viable structural alternative. Anisotropic NMR parameters, specifically residual dipolar coupling and residual chemical shift anisotropy data, were measured for caulamidine A and compared to DFT-calculated values for the proposed structure, the CASE-derived alternative structure, and two energetically feasible stereoisomers. Anisotropy-based NMR experiments provide a global, orthogonal means to verify complex structures free from investigator bias. The anisotropic NMR data were fully consistent with the assigned structure and configuration of caulamidine A. Caulamidine B has the same heterocyclic scaffold as A but a different composition and pattern of halogen substitution. Caulamidines A and B inhibited both wild-type and drug-resistant strains of the malaria parasite Plasmodium falciparum at low micromolar concentrations, yet were nontoxic to human cells.
Collapse
Affiliation(s)
- Dennis J Milanowski
- Molecular Targets Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA .
| | - Naoya Oku
- Molecular Targets Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA .
| | - Laura K Cartner
- Molecular Targets Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA . .,Basic Science Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research , Frederick , Maryland 21702-1201 , USA
| | - Heidi R Bokesch
- Molecular Targets Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA . .,Basic Science Program, Leidos Biomedical Research, Inc. , Frederick National Laboratory for Cancer Research , Frederick , Maryland 21702-1201 , USA
| | - R Thomas Williamson
- Structure Elucidation Group, Process and Analytical Research and Development , Merck & Co. Inc. , Rahway , New Jersey 07065 , USA .
| | - Josep Saurí
- Structure Elucidation Group, Process and Analytical Research and Development , Merck & Co. Inc. , Rahway , New Jersey 07065 , USA .
| | - Yizhou Liu
- Structure Elucidation Group, Process and Analytical Research and Development , Merck & Co. Inc. , Rahway , New Jersey 07065 , USA .
| | | | - Yuanqing Ding
- National Center for Natural Products Research , Department of BioMolecular Sciences , Division of Pharmacognosy , School of Pharmacy , University of Mississippi , Oxford , Mississippi 38655 , USA
| | - Xing-Cong Li
- National Center for Natural Products Research , Department of BioMolecular Sciences , Division of Pharmacognosy , School of Pharmacy , University of Mississippi , Oxford , Mississippi 38655 , USA
| | - Daneel Ferreira
- National Center for Natural Products Research , Department of BioMolecular Sciences , Division of Pharmacognosy , School of Pharmacy , University of Mississippi , Oxford , Mississippi 38655 , USA
| | - Larry A Walker
- National Center for Natural Products Research , Department of BioMolecular Sciences , Division of Pharmacognosy , School of Pharmacy , University of Mississippi , Oxford , Mississippi 38655 , USA
| | - Shabana Khan
- National Center for Natural Products Research , Department of BioMolecular Sciences , Division of Pharmacognosy , School of Pharmacy , University of Mississippi , Oxford , Mississippi 38655 , USA
| | | | - James A Kelley
- Chemical Biology Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA
| | - James B McMahon
- Molecular Targets Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA .
| | - Gary E Martin
- Structure Elucidation Group, Process and Analytical Research and Development , Merck & Co. Inc. , Rahway , New Jersey 07065 , USA .
| | - Kirk R Gustafson
- Molecular Targets Laboratory , Center for Cancer Research , National Cancer Institute , Frederick , Maryland 21702-1201 , USA .
| |
Collapse
|
35
|
Irie R, Takada K, Ise Y, Ohtsuka S, Okada S, Gustafson KR, Matsunaga S. Structure Revision of Poecillastrin C and the Absolute Configuration of the β-Hydroxyaspartic Acid Residue. Org Lett 2017; 19:5395-5397. [PMID: 28956931 DOI: 10.1021/acs.orglett.7b02835] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The planar structure of poecillastrin C (1) was revised through selective reduction of the ester carbon. The absolute configuration of the β-hydroxyaspartic acid (OHAsp) residue was determined to be d-threo by Marfey's analysis. The acid hydrolysate of the reduction product of 1 liberated (2R,3R)-2-amino-3,4-dihydroxybutanoic acid, demonstrating that the β-carboxyl group in poecillastrin C was esterified. The structures of poecillastrins B-D and 73-deoxychondropsin A were also revised.
Collapse
Affiliation(s)
- Raku Irie
- Laboratory of Aquatic Natural Products Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo , Bunkyo-ku, Tokyo 113-8657, Japan
| | - Kentaro Takada
- Laboratory of Aquatic Natural Products Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo , Bunkyo-ku, Tokyo 113-8657, Japan
| | - Yuji Ise
- Sugashima Marine Biological Laboratory, Nagoya University , Toba, Mie 517-0004, Japan
| | - Susumu Ohtsuka
- Takehara Marine Station, Hiroshima University , Takehara, Hiroshima 725-0024, Japan
| | - Shigeru Okada
- Laboratory of Aquatic Natural Products Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo , Bunkyo-ku, Tokyo 113-8657, Japan
| | - Kirk R Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute , Frederick, Maryland 21702, United States
| | - Shigeki Matsunaga
- Laboratory of Aquatic Natural Products Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo , Bunkyo-ku, Tokyo 113-8657, Japan
| |
Collapse
|
36
|
Zlotkowski K, Hewitt WM, Yan P, Bokesch HR, Peach ML, Nicklaus MC, O'Keefe BR, McMahon JB, Gustafson KR, Schneekloth JS. Macrophilone A: Structure Elucidation, Total Synthesis, and Functional Evaluation of a Biologically Active Iminoquinone from the Marine Hydroid Macrorhynchia philippina. Org Lett 2017; 19:1726-1729. [PMID: 28345939 DOI: 10.1021/acs.orglett.7b00496] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A previously uncharacterized pyrroloiminoquinone natural product, macrophilone A, was isolated from the stinging hydroid Macrorhynchia philippina. The structure was assigned utilizing long-range NMR couplings and DFT calculations and proved by a concise, five-step total synthesis. Macrophilone A and a synthetic analogue displayed potent biological activity, including increased intracellular reactive oxygen species levels and submicromolar cytotoxicity toward lung adenocarcinoma cells.
Collapse
Affiliation(s)
| | | | - Pengcheng Yan
- School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou, Zhejiang 325035, People's Republic of China
| | - Heidi R Bokesch
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States
| | - Megan L Peach
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States
| | | | | | | | | | | |
Collapse
|
37
|
Chan STS, Nani RR, Schauer EA, Martin GE, Williamson RT, Saurí J, Buevich AV, Schafer WA, Joyce LA, Goey AKL, Figg WD, Ransom TT, Henrich CJ, McKee TC, Moser A, MacDonald SA, Khan S, McMahon JB, Schnermann MJ, Gustafson KR. Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. J Org Chem 2016; 81:10631-10640. [PMID: 27934476 PMCID: PMC6350249 DOI: 10.1021/acs.joc.6b02380] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
An extract of Eudistoma sp. provided eudistidine C (1), a heterocyclic alkaloid with a novel molecular framework. Eudistidine C (1) is a racemic natural product composed of a tetracyclic core structure further elaborated with a p-methoxyphenyl group and a phenol-substituted aminoimidazole moiety. This compound presented significant structure elucidation challenges due to the large number of heteroatoms and fully substituted carbons. These issues were mitigated by application of a new NMR pulse sequence (LR-HSQMBC) optimized to detect four- and five-bond heteronuclear correlations and the use of computer-assisted structure elucidation software. Synthesis of eudistidine C (1) was accomplished in high yield by treating eudistidine A (2) with 4(2-amino-1H-imidazol-5-yl)phenol (4) in DMSO. Synthesis of eudistidine C (1) confirmed the proposed structure and provided material for further biological characterization. Treatment of 2 with various nitrogen heterocycles and electron-rich arenes provided a series of analogues (5-10) of eudistidine C. Chiral-phase HPLC resolution of epimeric eudistidine C provided (+)-(R)-eudistidine C (1a) and (-)-(S)-eudistidine C (1b). The absolute configuration of these enantiomers was assigned by ECD analysis. (-)-(S)-Eudistidine C (1b) modestly inhibited interaction between the protein binding domains of HIF-1α and p300. Compounds 1, 2, and 6-10 exhibited significant antimalarial activity against Plasmodium falciparum.
Collapse
Affiliation(s)
- Susanna T. S. Chan
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Roger R. Nani
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Evan A. Schauer
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Gary E. Martin
- NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - R Thomas Williamson
- NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Josep Saurí
- NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Alexei V. Buevich
- NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Wes A Schafer
- NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Leo A. Joyce
- NMR Structure Elucidation, Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Andrew K. L. Goey
- Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - William D. Figg
- Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Tanya T. Ransom
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Curtis J. Henrich
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Tawnya C. McKee
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Arvin Moser
- Advanced Chemistry Development, Inc. (ACD/Laboratories), Toronto Department, 8 King Street East Suite 107, Toronto, Ontario M5C 1B5, Canada
| | - Scott A. MacDonald
- Advanced Chemistry Development, Inc. (ACD/Laboratories), Toronto Department, 8 King Street East Suite 107, Toronto, Ontario M5C 1B5, Canada
| | - Shabana Khan
- National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Mississippi 38677, United States
| | - James B. McMahon
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Martin J. Schnermann
- Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
38
|
Zhao M, Cheng S, Yuan W, Xi Y, Li X, Dong J, Huang K, Gustafson KR, Yan P. Cembranoids from a Chinese Collection of the Soft Coral Lobophytum crassum. Mar Drugs 2016; 14:md14060111. [PMID: 27271640 PMCID: PMC4926070 DOI: 10.3390/md14060111] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 05/19/2016] [Accepted: 05/23/2016] [Indexed: 11/22/2022] Open
Abstract
Ten new cembrane-based diterpenes, locrassumins A–G (1–7), (–)-laevigatol B (8), (–)-isosarcophine (9), and (–)-7R,8S-dihydroxydeepoxysarcophytoxide (10), were isolated from a South China Sea collection of the soft coral Lobophytum crassum, together with eight known analogues (11–18). The structures of the new compounds were determined by extensive spectroscopic analysis and by comparison with previously reported data. Locrassumin C (3) possesses an unprecedented tetradecahydrobenzo[3,4]cyclobuta[1,2][8]annulene ring system. Compounds 1, 7, 12, 13, and 17 exhibited moderate inhibition against lipopolysaccharide (LPS)-induced nitric oxide (NO) production with IC50 values of 8–24 μM.
Collapse
Affiliation(s)
- Min Zhao
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
| | - Shimiao Cheng
- The Fifth Affiliated Hospital, Wenzhou Medical University, Lishui 323000, China.
| | - Weiping Yuan
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
| | - Yiyuan Xi
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
| | - Xiubao Li
- Key Laboratory of Marine Bio-Resources Sustainable Utilization, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China.
| | - Jianyong Dong
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
| | - Kexin Huang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
| | - Kirk R Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
| | - Pengcheng Yan
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
| |
Collapse
|
39
|
Goey AKL, Chau CH, Sissung TM, Cook KM, Venzon DJ, Castro A, Ransom TR, Henrich CJ, McKee TC, McMahon JB, Grkovic T, Cadelis MM, Copp BR, Gustafson KR, Figg WD. Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction. J Nat Prod 2016; 79:1267-75. [PMID: 27140429 PMCID: PMC6323635 DOI: 10.1021/acs.jnatprod.5b00846] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Inhibition of the hypoxia-inducible factor 1α (HIF-1α) pathway by disrupting its association with the transcriptional coactivator p300 inhibits angiogenesis and tumor development. Development of HIF-1α/p300 inhibitors has been hampered by preclinical toxicity; therefore, we aimed to identify novel HIF-1α/p300 inhibitors. Using a cell-free assay designed to test compounds that block HIF-1α/p300 binding, 170 298 crude natural product extracts and prefractionated samples were screened, identifying 25 active extracts. One of these extracts, originating from the marine sponge Latrunculia sp., afforded six pyrroloiminoquinone alkaloids that were identified as positive hits (IC50 values: 1-35 μM). Luciferase assays confirmed inhibition of HIF-1α transcriptional activity by discorhabdin B (1) and its dimer (2), 3-dihydrodiscorhabdin C (3), makaluvamine F (5), discorhabdin H (8), discorhabdin L (9), and discorhabdin W (11) in HCT 116 colon cancer cells (0.1-10 μM, p < 0.05). Except for 11, all of these compounds also reduced HIF-1α transcriptional activity in LNCaP prostate cancer cells (0.1-10 μM, p < 0.05). These effects occurred at noncytotoxic concentrations (<50% cell death) under hypoxic conditions. At the downstream HIF-1α target level, compound 8 (0.5 μM) significantly decreased VEGF secretion in LNCaP cells (p < 0.05). In COLO 205 colon cancer cells no activity was shown in the luciferase or cytotoxicity assays. Pyrroloiminoquinone alkaloids are a novel class of HIF-1α inhibitors, which interrupt the protein-protein interaction between HIF-1α and p300 and consequently reduce HIF-related transcription.
Collapse
Affiliation(s)
- Andrew K. L. Goey
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Cindy H. Chau
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Tristan M. Sissung
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Kristina M. Cook
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - David J. Venzon
- Biostatistics & Data Management Section, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Amaya Castro
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Tanya R. Ransom
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Curtis J. Henrich
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Tawnya C. McKee
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - James B. McMahon
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Tanja Grkovic
- School of Chemical Sciences, University of Auckland, Auckland 1142, New Zealand
| | - Melissa M. Cadelis
- School of Chemical Sciences, University of Auckland, Auckland 1142, New Zealand
| | - Brent R. Copp
- School of Chemical Sciences, University of Auckland, Auckland 1142, New Zealand
| | - Kirk R. Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - William D. Figg
- Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland 20892, United States
- Corresponding Author: Tel (W. D. Figg): +1-301-402-3623. Fax: +1-301-402-8606.
| |
Collapse
|
40
|
Yuan W, Cheng S, Fu W, Zhao M, Li X, Cai Y, Dong J, Huang K, Gustafson KR, Yan P. Structurally Diverse Metabolites from the Soft Coral Sinularia verruca Collected in the South China Sea. J Nat Prod 2016; 79:1124-1131. [PMID: 27010413 PMCID: PMC6328250 DOI: 10.1021/acs.jnatprod.6b00031] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Nineteen metabolites with diverse structures, including the rare pyrroloindoline alkaloid verrupyrroloindoline (1), the unprecedented highly fused benzosesquiterpenoid verrubenzospirolactone (2), the new asteriscane-type sesquiterpenoid 10-deoxocapillosanane D (3), and the two new cyclopentenone derivatives (4S*,5S*)-4-hydroxy-5-(hydroxymethyl)-2,3-dimethyl-4-pentylcyclopent-2-en-1-one (4) and (S)-4-hydroxy-5-methylene-2,3-dimethyl-4-pentylcyclopent-2-en-1-one (5), were isolated from a South China Sea collection of the soft coral Sinularia verruca. Eleven previously described marine metabolites (7-15, 18, and 19) were also obtained as well as three new EtOH-adduct artifacts (6, 16, and 17). The structures of the new compounds were elucidated by extensive spectroscopic analysis and by comparison with previously reported data. Compounds 4, 5, and 16 showed protection against the cytopathic effects of HIV-1 infection with EC50 values of 5.8-34 μM, and 4, 6, and 16 exhibited inhibition against LPS-induced NO production with IC50 values of 24-28 μM.
Collapse
Affiliation(s)
- Weiping Yuan
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
| | - Shimiao Cheng
- The Fifth Affiliated Hospital, Wenzhou Medical University, Lishui, Zhejiang 323000, People′s Republic of China
| | - Weitao Fu
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
| | - Min Zhao
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
| | - Xiubao Li
- Key Laboratory of Marine Bio-resources Sustainable Utilization, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, Guangdong 510301, People′s Republic of China
| | - Yuepiao Cai
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
| | - Jianyong Dong
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
| | - Kexin Huang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
| | - Kirk R. Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Pengcheng Yan
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People′s Republic of China
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
41
|
Forcina GC, Castro A, Bokesch HR, Spakowicz DJ, Legaspi ME, Kucera K, Villota S, Narvaez-Trujillo A, McMahon JB, Gustafson KR, Strobel SA. Stelliosphaerols A and B, Sesquiterpene-Polyol Conjugates from an Ecuadorian Fungal Endophyte. J Nat Prod 2015; 78:3005-3010. [PMID: 26651879 PMCID: PMC6318786 DOI: 10.1021/acs.jnatprod.5b00749] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Endophytic fungi are plant tissue-associated fungi that represent a rich resource of unexplored biological and chemical diversity. As part of an ongoing effort to characterize Amazon rainforest-derived endophytes, numerous fungi were isolated and cultured from plants collected in the Yasuní National Park in Ecuador. Of these samples, phylogenetic and morphological data revealed a previously undescribed fungus in the order Pleosporales that was cultured from the tropical tree Duroia hirsuta. Extracts from this fungal isolate displayed activity against Staphylococcus aureus and were thus subjected to detailed chemical studies. Two compounds with modest antibacterial activity were isolated, and their structures were elucidated using a combination of NMR spectroscopic analysis, LC-MS studies, and chemical degradation. These efforts led to the identification of stelliosphaerols A (1) and B (2), new sesquiterpene-polyol conjugates that are responsible, at least in part, for the S. aureus inhibitory activity of the fungal extract.
Collapse
Affiliation(s)
- Giovanni C. Forcina
- Department of Molecular Biophysics and BiochemistRy, Yale University, 260 Whitney Avenue, New Haven, Connecticut 06520-8114, United States
| | - Amaya Castro
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Heidi R. Bokesch
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland 21702-1201, United States
| | - Daniel J. Spakowicz
- Department of Molecular Biophysics and BiochemistRy, Yale University, 260 Whitney Avenue, New Haven, Connecticut 06520-8114, United States
| | - Michelle E. Legaspi
- Department of Molecular Biophysics and BiochemistRy, Yale University, 260 Whitney Avenue, New Haven, Connecticut 06520-8114, United States
| | - Kaury Kucera
- Department of Molecular Biophysics and BiochemistRy, Yale University, 260 Whitney Avenue, New Haven, Connecticut 06520-8114, United States
| | - Stephany Villota
- Laboratorio de Biotecnología Vegetal, Pontificia Universidad Católica del Ecuador, Quito 17 01 21 84, Ecuador
| | - Alexandra Narvaez-Trujillo
- Laboratorio de Biotecnología Vegetal, Pontificia Universidad Católica del Ecuador, Quito 17 01 21 84, Ecuador
| | - James B. McMahon
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Scott A. Strobel
- Department of Molecular Biophysics and BiochemistRy, Yale University, 260 Whitney Avenue, New Haven, Connecticut 06520-8114, United States
| |
Collapse
|
42
|
Henrich CJ, Cartner LK, Wilson JA, Fuller RW, Rizzo AE, Reilly KM, McMahon JB, Gustafson KR. Deguelins, Natural Product Modulators of NF1-Defective Astrocytoma Cell Growth Identified by High-Throughput Screening of Partially Purified Natural Product Extracts. J Nat Prod 2015; 78:2776-81. [PMID: 26467198 PMCID: PMC6352732 DOI: 10.1021/acs.jnatprod.5b00753] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
A high-throughput screening assay for modulators of Trp53/NF1 mutant astrocytoma cell growth was adapted for use with natural product extracts and applied to a novel collection of prefractionated/partially purified extracts. Screening 68 427 samples identified active fractions from 95 unique extracts, including the terrestrial plant Millettia ichthyotona. Only three of these extracts showed activity in the crude extract form, thus demonstrating the utility of a partial purification approach for natural product screening. The NF1 screening assay was used to guide purification of active compounds from the M. ichthyotona extract, which yielded the two rotenones deguelin (1) and dehydrodeguelin (2). The deguelins have been reported to affect growth of a number of cancer cell lines. They potently inhibited growth of only one of a panel of NF1/Trp53 mutant murine astrocytoma cell lines, possibly related to epigenetic factors, but had no effect on the growth of normal astrocytes. These results suggest the potential utility of deguelins as tools for further investigating NF1 astrocytoma cell growth. These bioprobes were identified only as a result of screening partially purified natural product extracts.
Collapse
Affiliation(s)
- Curtis J. Henrich
- Molecular Targets Laboratory, Center for Cancer Research, and National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
- Corresponding Authors: Tel (C. J. Henrich): +1-301-846-6054. Fax: +1-301-6122. ., Tel (K. R. Gustafson): +1-301-846-5197. Fax: +1-301-6851.
| | - Laura K. Cartner
- Molecular Targets Laboratory, Center for Cancer Research, and National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Jennifer A. Wilson
- Molecular Targets Laboratory, Center for Cancer Research, and National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Richard W. Fuller
- Molecular Targets Laboratory, Center for Cancer Research, and National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Anthony E. Rizzo
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Karlyne M. Reilly
- Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - James B. McMahon
- Molecular Targets Laboratory, Center for Cancer Research, and National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, and National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Corresponding Authors: Tel (C. J. Henrich): +1-301-846-6054. Fax: +1-301-6122. ., Tel (K. R. Gustafson): +1-301-846-5197. Fax: +1-301-6851.
| |
Collapse
|
43
|
Patridge EV, Darnell A, Kucera K, Phillips GM, Bokesch HR, Gustafson KR, Spakowicz DJ, Zhou L, Hungerford WM, Plummer M, Hoyer D, Narváez-Trujillo A, Phillips AJ, Strobel SA. Pyrrolocin A, a 3-Decalinoyltetramic Acid with Selective Biological Activity, Isolated from Amazonian Cultures of the Novel Endophyte Diaporthales sp. E6927E. Nat Prod Commun 2015; 10:1649-1654. [PMID: 26669095 PMCID: PMC7709712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
Natural products remain an important source of new therapeutics for emerging drug-resistant pathogens like Candida albicans, which particularly affects immunocompromised patients. A bioactive 3-decalinoyltetramic acid, pyrrolocin A, was isolated from extracts of a novel Amazonian fungal endophyte, E6927E, of the Diaporthales family. The structure of the natural product was solved using NMR and CD spectroscopy and it is structurally related to the fungal setins, equisetin and phomasetin, which are well-characterized tetramic acid antibiotics specific for Gram-positive organisms. We show that the compound inhibits growth of Staphylococcus aureus and Enterococcus faecalis. It shows selective and potent bioactivity against fungal strains, with an MIC of 4 μg/mL for C. albicans, 100 μg/mL for Aspergillus sp. and greater than 100 μg/mL for Saccharomyces cerevisiae. Further, the compound is less toxic to mammalian cells (IC50 = 150 μg/mL), with an inhibitory concentration greater than forty times that for C. albicans. Pyrrolocin A retained potent activity against eight out of seventeen strains of clinical Candida sp. isolates tested.
Collapse
|
44
|
Patridge EV, Darnell A, Kucera K, Phillips GM, Bokesch HR, Gustafson KR, Spakowicz DJ, Zhou L, Hungerford WM, Plummer M, Hoyer D, Narvaez-Trujillo A, Phillips AJ, Strobel SA. Pyrrolocin A, a 3-Decalinoyltetramic Acid with Selective Biological Activity, Isolated from Amazonian Cultures of the Novel Endophyte Diaporthales sp. E6927E. Nat Prod Commun 2015. [DOI: 10.1177/1934578x1501001006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Natural products remain an important source of new therapeutics for emerging drug-resistant pathogens like Candida albicans, which particularly affects immunocompromised patients. A bioactive 3-decalinoyltetramic acid, pyrrolocin A, was isolated from extracts of a novel Amazonian fungal endophyte, E6927E, of the Diaporthales family. The structure of the natural product was solved using NMR and CD spectroscopy and it is structurally related to the fungal setins, equisetin and phomasetin, which are well-characterized tetramic acid antibiotics specific for Gram-positive organisms. We show that the compound inhibits growth of Staphylococcus aureus and Enterococcus faecalis. It shows selective and potent bioactivity against fungal strains, with an MIC of 4 μg/mL for C. albicans, 100 μg/mL for Aspergillus sp. and greater than 100 μg/mL for Saccharomyces cerevisiae. Further, the compound is less toxic to mammalian cells (IC50 = 150 μg/mL), with an inhibitory concentration greater than forty times that for C. albicans. Pyrrolocin A retained potent activity against eight out of seventeen strains of clinical Candida sp. isolates tested.
Collapse
Affiliation(s)
- Eric V. Patridge
- Yale Center for Molecular Discovery, Yale University, West Haven, CT06516, USA
| | - Alicia Darnell
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
| | - Kaury Kucera
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
| | - Gillian M. Phillips
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
- Department of Chemistry, Yale University, New Haven, CT 06520, USA
| | - Heidi R. Bokesch
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
| | - Kirk R. Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
| | - Daniel J. Spakowicz
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
| | - Linda Zhou
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
| | | | - Mark Plummer
- Yale Center for Molecular Discovery, Yale University, West Haven, CT06516, USA
| | - Denton Hoyer
- Yale Center for Molecular Discovery, Yale University, West Haven, CT06516, USA
| | | | | | - Scott A. Strobel
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA
| |
Collapse
|
45
|
Shin HJ, Rashid MA, Cartner LK, Bokesch HR, Wilson JA, McMahon JB, Gustafson KR. Corrigendum to ‘Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge Stelletta sp.’ [Tetrahedron Lett. 56(28) (2015) 4215–4219]. Tetrahedron Lett 2015. [DOI: 10.1016/j.tetlet.2015.08.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Alan BD, Henrich CJ, Erickson KL, Thomas CL, Bokesch HR, Tewary P, Thompson CR, Pompei RJ, Gustafson KR, McMahon JB, Sayers TJ. Abstract 2928: Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-2928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Withanolide E (WE), a steroidal lactone from Physalis peruviana, was found to be highly active for sensitizing renal carcinoma cells and a number of other human cancer cells to TRAIL-mediated apoptosis. WE, the most potent and least toxic of 5 TRAIL sensitizing withanolides identified, enhanced death receptor-mediated apoptotic signaling via a rapid decline in the levels of both cFLIPL and cFLIPS proteins. Normal non-transformed human renal epithelial cells were completely resistant to the WE plus TRAIL combination. Other mechanisms by which TRAIL sensitizers have been reported to work: generation of reactive oxygen species (ROS), changes in various pro-and anti-apoptotic protein expression, death receptor upregulation, activation of intrinsic (mitochondrial) apoptotic pathways, ER stress, and proteasomal inhibition proved to be irrelevant to withanolide E activity. Loss of cFLIPL and cFLIPS was predominantly due to destabilization and/or aggregation of the proteins subsequently leading to their proteasomal degradation. Since cFLIPL and cFLIPS are reported to be HSP90 client proteins, and WE can inhibit HSP90 activity, the effect of WE on various other HSP90 client proteins was assessed. WE treatment of ACHN renal carcinoma cells altered the stability of a limited number of HSP90 client proteins when compared to the well-known HSP90 inhibitor geldanamycin. The destabilization of cFLIP proteins provides a potentially novel mechanism for sensitizing cancer cells to TRAIL mediated apoptosis. Sensitization of human renal carcinoma cells to TRAIL-induced apoptosis by WE and its lack of toxicity were confirmed in animal studies, in which a combination treatment of WE with an agonist antibody to TRAIL death receptor 5 (DR5) provided a significant therapeutic benefit compared to either agent alone in a renal cancer xenograft model. Due to its novel activity, WE is a promising reagent for analysis of mechanisms of TRAIL resistance, for understanding HSP90 function, and for further therapeutic development. Various structural analogs of WE are currently being tested for their TRAIL-sensitizing activity to provide more insight into Structure Activity Relationships (SAR) for these compounds. In marked contrast to bortezomib, among the best currently available TRAIL sensitizers, WE's more specific mechanism of action suggests minimal toxic side effects might accompany its combination with TRAIL death receptor agonists for cancer therapy.
Citation Format: Brooks D. Alan, Curtis J. Henrich, Karen L. Erickson, Cheryl L. Thomas, Heidi R. Bokesch, Poonam Tewary, Candace R. Thompson, Richard J. Pompei, Kirk R. Gustafson, James B. McMahon, Thomas J. Sayers. Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2928. doi:10.1158/1538-7445.AM2015-2928
Collapse
Affiliation(s)
- Brooks D. Alan
- 1Leidos Biomedical Research, Inc. / NCI-Frederick, Frederick, MD
| | | | | | | | - Heidi R. Bokesch
- 1Leidos Biomedical Research, Inc. / NCI-Frederick, Frederick, MD
| | - Poonam Tewary
- 1Leidos Biomedical Research, Inc. / NCI-Frederick, Frederick, MD
| | | | | | | | | | - Thomas J. Sayers
- 1Leidos Biomedical Research, Inc. / NCI-Frederick, Frederick, MD
| |
Collapse
|
47
|
Shin HJ, Rashid MA, Cartner LK, Bokesch HR, Wilson JA, McMahon JB, Gustafson KR. Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge Stelletta sp. Tetrahedron Lett 2015; 56:4215-4219. [PMID: 26139946 DOI: 10.1016/j.tetlet.2015.05.058] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Two new HIV-inhibitory depsipeptides, stellettapeptins A (1) and B (2), were isolated from an extract of the marine sponge Stelletta sp., collected from northwestern Australia. Structures of these cyclic nonribosomal peptides were elucidated on the basis of extensive NMR data analysis, and chemical degradation and derivatization studies. Stellettapeptins contain numerous nonproteinogenic amino acid residues and they are the first peptides reported to contain a 3-hydroxy-6,8-dimethylnon-4-(Z)-enoic acid moiety. Compounds 1 and 2 potently inhibit infection of human T-lymphoblastoid cells by HIV-1RF with EC50 values of 23 and 27 nM, respectively.
Collapse
Affiliation(s)
- Hee Jae Shin
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA
| | - Mohammad A Rashid
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA
| | - Laura K Cartner
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA ; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA
| | - Heidi R Bokesch
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA ; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA
| | - Jennifer A Wilson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA
| | - James B McMahon
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA
| | - Kirk R Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA
| |
Collapse
|
48
|
Chan STS, Patel PR, Ransom TR, Henrich CJ, McKee TC, Goey AKL, Cook KM, Figg WD, McMahon JB, Schnermann MJ, Gustafson KR. Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α. J Am Chem Soc 2015; 137:5569-75. [PMID: 25892103 DOI: 10.1021/jacs.5b02156] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Low oxygen environments are a hallmark of solid tumors, and transcription of many hypoxia-responsive genes needed for survival under these conditions is regulated by the transcription factor HIF-1 (hypoxia-inducible factor 1). Activation of HIF-1 requires binding of its α-subunit (HIF-1α) to the transcriptional coactivator protein p300. Inhibition of the p300/HIF-1α interaction can suppress HIF-1 activity. A screen for inhibitors of the protein binding domains of p300 (CH1) and HIF-1α (C-TAD) identified an extract of the marine ascidian Eudistoma sp. as active. Novel heterocyclic alkaloids eudistidines A (1) and B (2) were isolated from the extract, and their structures assigned by spectroscopic analyses. They contain an unprecedented tetracyclic core composed of two pyrimidine rings fused with an imidazole ring. Eudistidine A (1) was synthesized in a concise four-step sequence featuring a condensation/cyclization reaction cascade between 4-(2-aminophenyl)pyrimidin-2-amine (3) and 4-methoxy-phenylglyoxal (4), while eudistidine B (2) was synthesized in a similar fashion with glyoxylic acid (5) in place of 4. Naturally occurring eudistidine A (1) effectively inhibited CH1/C-TAD binding with an IC50 of 75 μM, and synthetic 1 had similar activity. The eudistidine A (1) scaffold, which can be synthesized in a concise, scalable manner, may provide potential therapeutic lead compounds or molecular probes to study p300/HIF-1α interactions and the role these proteins play in tumor response to low oxygen conditions. The unique structural scaffolds and functional group arrays often found in natural products make these secondary metabolites a rich source of new compounds that can disrupt critical protein-protein binding events.
Collapse
Affiliation(s)
- Susanna T S Chan
- †Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Paresma R Patel
- ‡Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.,§National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Tanya R Ransom
- †Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Curtis J Henrich
- †Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States.,⊥Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - Tawnya C McKee
- †Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Andrew K L Goey
- ∥Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - Kristina M Cook
- ∥Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - William D Figg
- ∥Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States
| | - James B McMahon
- †Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Martin J Schnermann
- ‡Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R Gustafson
- †Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
49
|
Sunassee S, Ransom T, Henrich C, Beutler JA, Covell DG, McMahon JB, Gustafson KR. Steroidal alkaloids from the marine sponge Corticium niger that inhibit growth of human colon carcinoma cells. J Nat Prod 2014; 77:2475-80. [PMID: 25338277 PMCID: PMC4251534 DOI: 10.1021/np500556t] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Indexed: 05/25/2023]
Abstract
Bioinformatic analysis of data from the NCI-60 cell cytotoxicity screen revealed a subset of extracts that showed selective cytotoxic activity toward human colon carcinoma cell lines. Bioassay-guided fractionation of a colon cancer selective extract from a Philippines collection of the marine sponge Corticium niger provided two new steroidal alkaloids, plakinamines N (1) and O (2), along with two known compounds of the plakinamine class (3, 4). The structures of these compounds were elucidated by interpretation of combined MS and NMR spectroscopic data. Plakinamines N (1), O (2), and J (4) were tested for antiproliferative activity in the NCI-60 screen, and they showed enhanced inhibitory effects against all of the colon cell lines with mean GI50 values of 11.5, 2.4, and 1.4 μM, respectively.
Collapse
Affiliation(s)
- Suthananda
N. Sunassee
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Tanya Ransom
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Curtis
J. Henrich
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
- Basic
Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702-1201, United States
| | - John A. Beutler
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - David G. Covell
- Screening
Technologies Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - James B. McMahon
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| | - Kirk R. Gustafson
- Molecular
Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
| |
Collapse
|
50
|
Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauss TF, Dong Z, Gustafson KR, Biondi RM, Henrich CJ, McMahon JB, Colburn NH, Schmid T, Brüne B. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor. Biochem Pharmacol 2014; 88:313-21. [PMID: 24513322 DOI: 10.1016/j.bcp.2014.01.034] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 01/08/2014] [Accepted: 01/24/2014] [Indexed: 01/03/2023]
Abstract
Deregulation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR)-70kDa ribosomal protein S6 kinase 1 (p70(S6K)) pathway is commonly observed in many tumors. This pathway controls proliferation, survival, and translation, and its overactivation is associated with poor prognosis for tumor-associated survival. Current efforts focus on the development of novel inhibitors of this pathway. In a cell-based high-throughput screening assay of 15,272 pure natural compounds, we identified pomiferin triacetate as a potent stabilizer of the tumor suppressor programmed cell death 4 (Pdcd4). Mechanistically, pomiferin triacetate appeared as a general inhibitor of the PI3K-Akt-mTOR-p70(S6K) cascade. Interference with this pathway occurred downstream of Akt but upstream of p70(S6K). Specifically, mTOR kinase emerged as the molecular target of pomiferin triacetate, with similar activities against mTOR complexes 1 and 2. In an in vitro mTOR kinase assay pomiferin triacetate dose-dependently inhibited mTOR with an IC50 of 6.2 μM. Molecular docking studies supported the interaction of the inhibitor with the catalytic site of mTOR. Importantly, pomiferin triacetate appeared to be highly selective for mTOR compared to a panel of 17 lipid and 50 protein kinases tested. As a consequence of the mTOR inhibition, pomiferin triacetate efficiently attenuated translation. In summary, pomiferin triacetate emerged as a novel and highly specific mTOR inhibitor with strong translation inhibitory effects. Thus, it might be an interesting lead structure for the development of mTOR- and translation-targeted anti-tumor therapies.
Collapse
Affiliation(s)
- Magdalena M Bajer
- Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany
| | - Michael M Kunze
- Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany
| | - Johanna S Blees
- Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany
| | - Heidi R Bokesch
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - Hanyong Chen
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
| | - Thilo F Brauss
- Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany
| | - Zigang Dong
- The Hormel Institute, University of Minnesota, Austin, MN 55912, USA
| | - Kirk R Gustafson
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA
| | - Ricardo M Biondi
- Research Group PhosphoSites, Department of Internal Medicine I, University Clinic, 60590 Frankfurt, Germany
| | - Curtis J Henrich
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
| | - James B McMahon
- Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA
| | - Nancy H Colburn
- Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA
| | - Tobias Schmid
- Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany.
| | - Bernhard Brüne
- Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany
| |
Collapse
|